Development of antimetastatic drugs by targeting tumor sialic acids

Area of Science:

• Oncology
• Cancer Metastasis Research
• Drug Discovery

Background:

• Neoplasm metastasis occurs in one-third of cancer cases and is a primary cause of cancer-related mortality.
• Current therapeutic strategies for metastasis are largely unsatisfactory, with limited benefits observed in late-stage or elderly patients.
• A significant challenge is the lack of specific therapeutic targets for neoplasm metastasis.

Purpose of the Study:

• To review and discuss novel therapeutic approaches targeting sialic acids in metastatic tissues.
• To highlight the potential of antimetastatic drugs that target aberrant sialylation in tumors.
• To address the urgent need for new drug-screening pathways beyond current antimetastatic agents.

Main Methods:

• Review of existing literature on therapeutic strategies for neoplasm metastasis.
• Analysis of the role of aberrant sialylation and sialic acid analogues (e.g., N-glycolylneuraminic acid) in tumor tissues.
• Discussion of six distinct therapeutic approaches targeting sialic acids in metastatic cancers.

Main Results:

• Neoplasm tissues frequently exhibit elevated levels of sialic acids and sialyl antigens.
• Sialic acid analogues, like N-glycolylneuraminic acid (Nau5Gc), are present in tumor tissues but typically absent in normal human tissues.
• Targeting aberrantly sialylated structures in tumors represents a developing therapeutic avenue.

Conclusions:

• Antimetastatic drugs targeting aberrant sialylation are a potential future therapeutic option.
• These approaches may offer advantages over current treatments like antivascular agents and MMP inhibitors.
• Further research and development of therapies targeting sialic acid modifications in metastasis are crucial.